Lisata authorizes board to choose reverse stock split of up to 1-for-15
Key Facts
Lisata Therapeutics authorized its board to choose a reverse stock split ratio ranging from 1-for-5 to 1-for-15, according to a company filing with the U.S. Securities and Exchange Commission. Shareholders approved the proposal at a November 9, 2026, meeting, according to the voting results in the filing. The authorization allows the board to select a ratio within that range without returning to shareholders for additional approval. The filing alone does not establish that a specific ratio has been chosen or set an implementation date. The decision places the measure within the governance authority approved by shareholders, while leaving the timing and ratio selection to the board.
The proposal received 7,524,706 votes in favor, 443,844 votes against and 204,118 abstentions. These figures appear in the voting record for the November 9 meeting at which the authorization was approved. Under the approved authority, the board may choose a ratio from 1-for-5 to 1-for-15. This means the authorization set the limits of the possible ratio without making the upper limit an effective decision in itself. The voting record in the filing also does not provide a separate figure setting an implementation date.
The company had 10,804,066 common shares outstanding on October 9, 2026, according to its filing. That figure applies to that date and is not a stated count of shares that may remain after any split chosen by the board. The available filing does not provide an expected share count after application of a specific ratio. The record also does not specify a method for handling fractional shares or a reference price for compensating shareholders for them. Those details remain subject to any subsequent implementation announcement by the company.
Lisata Therapeutics shares, trading under the ticker LSTA, closed at $0.98 on November 18, according to the historical prices page of its investor relations site. The stock reached a session high of $1.11 and a low of $0.89. These prices relate to the November 18 session, and the page does not report an effect from an implemented split in the data provided. The official filing available here does not link the stock’s movement in that session to the authorization or to a selected ratio. The recorded price is a snapshot of the market that day, while the board will determine the ratio within the range approved by shareholders.
Shareholders granted the board the authority without reducing the number of shares authorized for issuance, according to the text of the authorization. This means the decision on the split ratio does not itself amend the authorized share limit. The filing distinguishes the authorized ratio range from the board’s selection of a specific ratio, allowing it to act within the approved limits without another vote. The available filing does not establish that a ratio has been selected or an effective date set. It also does not state the resulting share count from any potential split.
As background on the company’s financial position, Lisata said it completed a private placement on September 18, 2026, in connection with its acquisition of Marea, generating gross proceeds of $225 million. It said the financing was carried out through the sale of convertible Series C preferred shares, subject to the relevant terms and approvals. This financing is separate from the reverse split authorization and does not by itself determine the ratio the board will choose. The proceeds disclosure does not provide details on the expected number of common shares after any split.
According to the company’s statement on the proposal, each shareholder is expected to retain the same ownership percentage of the outstanding common shares immediately after the split as before it, subject to possible minor adjustments in the handling of fractional shares. This describes the ownership percentage and does not change the nominal number of shares held by an investor when a reverse split is applied. The available public filing here does not specify how fractions will be settled or what price will be used. These effects depend on the board selecting a specific ratio and announcing implementation details. The range approved by shareholders remains between 1-for-5 and 1-for-15.